TRK-IN-18

Modify Date: 2024-04-03 17:11:57

TRK-IN-18 structure	Common Name	TRK-IN-18
	CAS Number	2412008-91-2	Molecular Weight	495.54
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₅H₂₃F₂N₅O₂S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of TRK-IN-18

TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7)[1].

Name	TRK-IN-18

Description	TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Trk Receptor
References	[1]. Nicola ROBAS, et al. Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds. Paatent WO2021148805A1.

Molecular Formula	C₂₅H₂₃F₂N₅O₂S
Molecular Weight	495.54

TRK-IN-18

Use of TRK-IN-18

Names

TRK-IN-18 Biological Activity

Chemical & Physical Properties